Avagacestat , 10mMinDMSO , 1146699-66-2

Synonym(s):
(2R)-2-[N-[(4-Chlorophenyl)sulfonyl]-N-[[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide;(R)-2-(4-Chloro-N-(2-fluoro-4-(1,2,4-oxadiazol-3-yl)benzyl)phenylsulfonamido)-5,5,5-trifluoropentanamide;BMS-708163

CAS NO.：1146699-66-2

Empirical Formula: C20H17ClF4N4O4S

Molecular Weight: 520.89

MDL number: MFCD13195458

PRODUCT Properties

• Density: 1.488
• storage temp.: Store at -20°C
• solubility: insoluble in H2O; ≥177.6 mg/mL in DMSO; ≥47.6 mg/mL in EtOH with ultrasonic
• form: Powder
• color: White to off-white
• InChIKey: XEAOPVUAMONVLA-QGZVFWFLSA-N
• SMILES: NC([C@@H](CCC(F)(F)F)N(S(C1=CC=C(Cl)C=C1)(=O)=O)CC2=C(F)C=C(C3=NOC=N3)C=C2)=O

Description and Uses

Avagacestat acts as a γ-secretase inhibitor allowing for treatment of ALzheimer’s disease. On addition it has seen uses targeting embryonic signaling pathways, which control stem cell and cellular development process in cancer therapy.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H315-H319-H335
• Precautionary statements: P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P321-P362+P364-P332+P313-P337+P313-P403+P233-P405-P501
• target organs: Respiratory system
• WGK Germany: WGK 3
• Storage Class: 11 - Combustible Solids
• Hazard Classifications: Eye Irrit. 2; Skin Irrit. 2; STOT SE 3